Contact Us

Neurontin
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date you started taking this drug:

Date you stopped taking this drug:

Was suicide attempted?

Did loved one commit suicide?

What condition was this medication prescribed to treat?

What additional medications were you taking at the time?

If patient did commit suicide, what was the method of suicide?

If patient did attempt or commit suicide, did patient ever attempt suicide previously?

Please describe any psychiatric conditions diagnosed before starting Neurontin:

Did Neurontin help the condition that it was prescribed for?


Please further describe side effects:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


F.D.A. Is Looking Into Epilepsy Drugs

Apr 22, 2005 | AP

The Food and Drug Administration has begun a preliminary inquiry into whether epilepsy drugs may increase the risk of suicidal behavior in some patients, particularly those who use them for psychiatric illnesses.

Prompted in part by a lawyer's claims against a leading anticonvulsant, Neurontin, the F.D.A. asked makers of all epilepsy medicines last month to reanalyze research to see if there was evidence of increased suicide risk.

"I don't think we have any suspicion yet that these drugs actually do that," said Dr. Robert Temple, the F.D.A.'s drug policy chief.

Antiseizure drugs are becoming widely used to treat some psychiatric illnesses as well as pain.


Related articles Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo